{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:11:38Z","timestamp":1791277898805,"version":"4.1.0"},"reference-count":34,"publisher":"Impact Journals, LLC","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,6,7]]},"DOI":"10.18632\/oncotarget.9182","type":"journal-article","created":{"date-parts":[[2016,5,6]],"date-time":"2016-05-06T20:04:06Z","timestamp":1462565046000},"page":"35293-35301","source":"Crossref","is-referenced-by-count":64,"title":["Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation"],"prefix":"10.18632","volume":"7","author":[{"given":"Jean Claude","family":"Chomel","sequence":"first","affiliation":[{"name":"Laboratoire de Canc\u00e9rologie Biologique, CHU de Poitiers, Poitiers, France"},{"name":"INSERM U935, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Laure","family":"Bonnet","sequence":"additional","affiliation":[{"name":"INSERM U935, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Sorel","sequence":"additional","affiliation":[{"name":"Laboratoire de Canc\u00e9rologie Biologique, CHU de Poitiers, Poitiers, France"},{"name":"INSERM U935, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Sloma","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Biologique, H\u00f4pital Paul Brousse, Villejuif, France"},{"name":"INSERM U935, Villejuif, France"},{"name":"Universit\u00e9 Paris Sud, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelise","family":"Bennaceur-Griscelli","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Biologique, H\u00f4pital Paul Brousse, Villejuif, France"},{"name":"INSERM U935, Villejuif, France"},{"name":"Universit\u00e9 Paris Sud, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Rea","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Adulte, H\u00f4pital Saint Louis, Paris, France"},{"name":"INSERM UMRS-1160, IUH-Universit\u00e9 Paris Diderot-Paris 7, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Legros","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique, H\u00f4pital l'Archet, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Marfaing-Koka","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Biologique, H\u00f4pital Antoine B\u00e9cl\u00e8re, Clamart, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Henri","family":"Bourhis","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Biologique, H\u00f4pital Antoine B\u00e9cl\u00e8re, Clamart, France"},{"name":"Service d'H\u00e9matologie-Greffe de Moelle, Institut Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanti","family":"Ame","sequence":"additional","affiliation":[{"name":"D\u00e9partement d'H\u00e9matologie et Oncologie, H\u00f4pitaux Universitaires de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Guerci-Bresler","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique, CHU Brabois, Vandoeuvre les Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie et Oncologie, Centre Hospitalier de Versailles, Versailles, France"},{"name":"EA4340, Universit\u00e9 Versailles-Saint Quentin en Yvelines, Universit\u00e9 Paris-Saclay, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali G.","family":"Turhan","sequence":"additional","affiliation":[{"name":"INSERM U935, Poitiers, France"},{"name":"Service d'H\u00e9matologie Biologique, H\u00f4pital Paul Brousse, Villejuif, France"},{"name":"INSERM U935, Villejuif, France"},{"name":"Universit\u00e9 Paris Sud, Le Kremlin-Bic\u00eatre, France"},{"name":"Service d'H\u00e9matologie, H\u00f4pital Bic\u00eatre, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,5,5]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Saglio","year":"2012","journal-title":"Leukemia"},{"key":"2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Bradley-Garelik","year":"2014","journal-title":"Blood"},{"key":"3","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1002\/cncr.27506","article-title":"Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy","volume":"118","author":"Rosti","year":"2012","journal-title":"Cancer"},{"key":"4","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/leu.2013.19","article-title":"Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients","volume":"27","author":"Markevarn","year":"2013","journal-title":"Leukemia"},{"key":"5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Holyoake","year":"2002","journal-title":"Blood"},{"key":"6","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Holyoake","year":"2006","journal-title":"Blood"},{"key":"7","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"Holyoake","year":"2007","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2008-08-176016","article-title":"Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib","volume":"114","author":"Martin-Padura","year":"2009","journal-title":"Blood"},{"key":"9","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Melo","year":"2010","journal-title":"Leukemia"},{"key":"10","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2009-11-255109","article-title":"In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib","volume":"116","author":"Melo","year":"2010","journal-title":"Blood"},{"key":"11","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Druker","year":"2011","journal-title":"J Clin Invest"},{"key":"12","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Holyoake","year":"2012","journal-title":"Blood"},{"key":"13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Rousselot","year":"2010","journal-title":"Lancet Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"White","year":"2013","journal-title":"Blood"},{"key":"15","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1182\/blood.V122.21.654.654","article-title":"Preliminary Report Of The STIM2 Study: A Multicenter Stop Imatinib Trial For Chronic Phase Chronic Myeloid Leukemia De Novo Patients On Imatinib","volume":"122","author":"Dulucq","year":"2013","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM198306233082502","article-title":"Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia","volume":"308","author":"Eaves","year":"1983","journal-title":"N Engl J Med"},{"key":"17","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2010-08-303495","article-title":"Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib","volume":"119","author":"Burchert","year":"2012","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1182\/blood-2011-12-396226","article-title":"BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia","volume":"119","author":"Turhan","year":"2012","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Turhan","year":"2011","journal-title":"Blood"},{"key":"20","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Bhatia","year":"2011","journal-title":"Blood"},{"key":"21","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Tulliez","year":"2014","journal-title":"J Clin Oncol"},{"key":"22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-07-0042","article-title":"CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells","volume":"7","author":"Konopleva","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"23","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3324\/haematol.2009.017178","article-title":"Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4\/CXCL12 axis","volume":"95","author":"Dazzi","year":"2010","journal-title":"Haematologica"},{"key":"24","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia","volume":"123","author":"Sperr","year":"2014","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/eci.12368","article-title":"DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia","volume":"44","author":"Mayer","year":"2014","journal-title":"Eur J Clin Invest"},{"key":"26","doi-asserted-by":"crossref","first-page":"16280","DOI":"10.1073\/pnas.1004408107","article-title":"Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein","volume":"107","author":"Fioretos","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"27","first-page":"4787","article-title":"IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients","volume":"7","author":"Xu","year":"2014","journal-title":"Int J Clin Exp Med"},{"key":"28","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2012-01-405373","article-title":"Too much BCR-ABL to live on, but too little BCR-ABL to die on?","volume":"119","author":"Hochhaus","year":"2012","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.exphem.2015.08.004","article-title":"Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients","volume":"43","author":"Carcassi","year":"2015","journal-title":"Exp Hematol"},{"key":"30","first-page":"856","article-title":"Low Natural Killer (NK) cell counts and functionality are associated with molecular relapse after Imatinib discontinuation in patients with Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) with undetectable BCR-ABL transcripts for at least 2 years","volume":"122","author":"Toubert","year":"2013","journal-title":"Blood"},{"key":"31","doi-asserted-by":"crossref","first-page":"e28861","DOI":"10.4161\/onci.28861","article-title":"Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse","volume":"3","author":"Ohyashiki","year":"2014","journal-title":"Oncoimmunology"},{"key":"32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrclinonc.2011.17","article-title":"Hematology: curing CML with imatinib--a dream come true","volume":"8","author":"Deininger","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/asheducation-2011.1.136","article-title":"Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure","volume":"2011","author":"Ross","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"34","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Pallisgaard","year":"2015","journal-title":"Leukemia"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T21:24:15Z","timestamp":1589232255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,5]]},"references-count":34,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2016,6,7]]}},"alternative-id":["9182","27167108"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.9182","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,5]]}}}